Rossari Biotech Ltd - 543213 - Outcome Of Board Meeting Held On Saturday, April 29, 2023
The Board of Directors have Inter alia approved Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023 of the Financial Year 2022-23 and other matters. Rossari Biotech Ltd - 543213 - Board Meeting Outcome for Outcome Of Board Meeting Held On Saturday, April 29, 2023.
The Board of Directors have Inter alia approved Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023 of the Financial Year 2022-23 and other matters. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Earnings Conference Call for investors and analysts on Tuesday, May 02, 2023 at 05:00 P.M. IST Rossari Biotech Ltd - 543213 - Board Meeting Intimation for Considering And Approving Audited Financial Statements And Financial Results (Standalone And Consolidated) For The Quarter And Financial Year Ended March 31, 2023 And Dividend (If Any)
Rossari Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/04/2023 ,inter alia, to consider and approve Audited Financial Statements and Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2023 and Dividend (if any) Rossari Biotech Ltd - 543213 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyRossari Biotech Ltd 2CIN NO.L24100MH2009PLC194818 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 64.92 4Highest Credit Rating during the previous FY AA- 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Ms Parul Gupta Designation: Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Ms Manasi Nisal Designation: Chief Financial Officer EmailId: [email protected] Date: 21/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. Rossari Biotech Ltd - 543213 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on Acquisition of Tristar Intermediates Private Limited. Rossari Biotech Ltd - 543213 - Clarification With Respect To Increase In Volume
This is with reference to the National Stock Exchange of India Limited's Letter no. NSE/CM/Surveillance/12929, dated April 10, 2023 received though email on April 10, 2023, seeking clarification in the matter of increase in volume of equity shares of the Company, in the recent past, as traded across exchanges. Rossari Biotech Ltd - 543213 - Compliance Certificate Under Regulation 7(3) Of Listing Regulations
Compliance certificate under Regulation 7(3) of Listing Regulations for the year ended March 31, 2023. Rossari Biotech Ltd - 543213 - Compliance Certificate Pursuant To Regulation 40 (10)
Compliance certificate issued by Mr. Sanjay Dholakia of Sanjay Dholakia & Associates, Practicing Company Secretaries, for the period April 01, 2022 to March 31, 2023.